Inducible gene-targeting experiments have shown that Ig expression is essential for maintaining survival of mature B cells, but the role of Ig expression in immature B cell survival has not been determined. To assess whether continued B cell receptor (BCR) expression is required for bone marrow B cell precursor development and survival, we developed a method for conditional gene deletion in these cells. Recombination-activating gene regulatory elements were used to express Ig␤ cDNA as a transgene to complement Ig␤ ؊/؊ mice. Transgenic Ig␤ expression was found in proB and small preB cells and was extinguished in large preB and immature B cells. Ig␤ deletion from large preB cells and immature B cells resulted in cell death that could be rescued by transgenic bcl-2 expression. However, transgenic bcl-2 expression was unable to restore B cell development in the absence of Ig␤. We conclude that Ig␤ expression is essential to maintain preB cell and immature B cell survival and to mediate B cell differentiation. In addition, complementation of null mutations with cDNAs under the control of heterologous bacterial artificial chromosomes is a useful method for cell-type-specific and developmentally regulated gene ablation in vivo.
. It was proposed that cell death in response to Ig ablation is an important mechanism for B lymphocyte quality control in the periphery leading, for example, to deletion of B cells that accumulate deleterious mutations in their Ig genes during the germinal center reaction (4) . In contrast, T cells lacking T cell antigen receptor (TCR) do not die precipitously suggesting that requirement of BCR and TCR expression was different in B and T lymphocyte survival, respectively (5, 6) .
Immature B cells differ from mature B cells in their responses to BCR crosslinking. Whereas BCR stimulation in mature B cells leads to clonal expansion, the same stimulus leads to tolerance in immature B cells. In the bone marrow, a large fraction of developing B cells undergo receptor editing, and an unknown number of these cells lose BCR expression by out-of-frame or RS V(D)J recombination (7) (8) (9) . Therefore, programmed cell death in response to receptor deletion would serve the same qualitycontrol purpose in developing B cells. However, the role of Ig and BCR expression in immature B cell survival could not be examined by conventional conditional gene targeting because Ig deletion by inducible Cre ablates normal B cell development (4).
To determine whether BCR expression in preB cells and immature B cells is required to induce their further differentiation and to maintain their survival, we developed a method for terminating Ig␤ expression in developing B cells in the bone marrow.
Materials and Methods
Transgenic Mice. A bacterial artificial chromosome (BAC) containing RAG1 and RAG2 genes and all of the regulatory elements required to direct RAG expression in vivo was used to generate an Ig␤ transgene [N-BAC (10)]. Mouse Ig␤ cDNA was inserted at the RAG2 start codon in N-BAC by homologous recombination (11) and used to produce transgenic mice (Ig␤tg).
, and bcl-2-Ig␤tg-Ig␤ Ϫ/Ϫ mice (12) (13) (14) were produced by breeding. All mice were maintained under specific pathogen-free conditions. Flow Cytometry and Cell Sorting. Bone marrow and spleen B cells from mutant or wild-type mice were enriched by positive selection by using MACS CD19 microbeads (Miltenyi Biotec, Auburn, CA) and stained with FITC, phycoerythrin, allophycocyanin, and biotin-conjugated monoclonal antibodies that were visualized with Strepavidin red 613 (GIBCO͞BRL). Monoclonal antibodies were anti-CD43, anti-IgM, anti-B220, anti-CD25, anti-IgD, anti-HSA, anti-CD19, and anti-CD22 (PharMingen). Data were collected on a FACScalibur and analyzed with CELLQUEST software (Becton Dickinson).
RNA Preparation and Reverse Transcription (RT)-PCR.
Total RNA was extracted from 10 5 purified B cells by using TRIzol Reagent (GIBCO͞BRL) and reverse transcribed in 20 l with Superscript II (GIBCO͞BRL). For RT-PCR reactions, 1 l of cDNA was amplified for either16 cycles (actin) or 30 cycles of 30 s at 94°C, 30 s at 60°C, and 30 s at 72°C with a final 10-min extension at 72°C with Hotstar TaqDNA polymerase (Qiagen, Chatsworth, CA) and the following primers: Ig␣ sense 5Ј-CGATGC-CAGGGGGTCTAGAAG-3Ј, antisense 5Ј-GAAGAACAGCT-GGCCTGTGGTA-3Ј; Ig␤ sense and antisense as Ig␤tg primers above (see Transgenic Mice). RAG1-, RAG2-, and ␤-actinspecific primers have been described (15) . Transgenic Ig␤ expression in wild-type background was detected by RT-PCR by using 5Ј sense RAG2 and Ig␤ antisense primers. RT-PCR products were analyzed on 2% agarose gels and Southern blots were hybridized with cognate cDNAs. Phosphorimager analysis was performed on PCR samples amplified in the linear range. 6 ͞ml with irradiated S17 stromal cells in DMEM supplemented with 10% FCS and 10 ng͞ml IL-7 (PharMingen). B cell viability was assessed by flow cytometry after phycoerythrinAnnexin V (PharMingen) and propidium iodide staining on day 0 and after a 36-h culture period. Ig␤ cDNA into RAG2 in a RAG locus containing bacterial artificial chromosome (11) . Two Ig␤ transgenic lines were obtained and showed identical patterns of transgenic Ig␤ expression (Ig␤tg mice, Fig. 1A ).
Results

Ig␤
To determine whether Ig␤tg expression resembles the documented pattern of endogenous RAG2 expression, we measured transgenic Ig␤ mRNA by RT-PCR (Fig. 1B) . Like endogenous RAG2, high levels of the transgenic mRNA were detected in proB cells, expression was down-regulated in proliferating (large) preB cells, reinduced in resting (small) preB cells ( (Fig. 2) . The few B cells that were found in the spleen resembled their immature bone marrow counterparts in that they expressed low levels of surface IgM, IgD, and CD25 ( Fig. 3 A and  B) and low levels of endogenous RAG1 and RAG2 genes (Fig.  3C) . As expected the level of transgenic Ig␤ mRNA in these cells was low and similar to the level of endogenous RAG2, whereas Ig␣ and actin expression was similar to control ( mice and controls were purified and cell death measured by staining with annexin V and propidium iodide at the initiation of culture and after 36 h (19) . Annexin V staining varies during B cell development and is therefore unreliable when comparing B cells in different stages (19) . However, annexin is a reliable marker for apoptosis when comparing cells at similar stages in development.
Freshly isolated Ig␤ Ϫ/Ϫ proB cells showed a 2-fold increase in annexin V and propidium iodide staining compared with wildtype controls (Fig. 4 A and B) . During a 36-h culture period, Ig␤ Ϫ/Ϫ proB cells failed to develop, whereas control proB cells progressed to the immature B cell stage (Fig. 4 A and B) . Freshly isolated Ig␤tg-Ig␤ Ϫ/Ϫ preB cells showed a 5-fold increase in annexin V staining compared with controls ( Fig. 4 C and D) . (Fig. 4 C and D) . Freshly isolated immature B cells differed from pro-and preB cells in that both mutants and controls showed high levels of annexin staining (Fig. 4 E and F) . (Fig. 4E) . Annexin V and propidium iodide staining after 36 h revealed an increase in apoptotic and dead cells in ␣HEL-Ig␤tg-Ig␤ Ϫ/Ϫ immature B cell cultures compared with wild-type controls (Fig. 4F) . We conclude that Ig␤ deletion in preB or immature B cells results in both arrested B cell development and cell death. (Fig. 5A) . These B cells survived long enough to populate the spleen in bcl-2 transgenic ␣HEL-Ig␤tg-Ig␤ (Fig. 5B) . Thus, bcl-2 transgene expression rescues preB and immature B cells from cell death in response to Ig␤ deletion but fails to induce further B cell differentiation.
Discussion
Gene Ablation by BAC Complementation. Inducible gene targeting is an established method for altering specific gene expression in fully developed tissues in mice (21) . The advantage of this method compared with conventional gene targeting is that it allows the target gene to contribute to normal cellular maturation before deletion. Disadvantages of conditional gene targeting are that the deletion is frequently less than 100% efficient, it requires inducing agents such as IFN that may alter normal physiology, and high levels of cre recombinase expression can damage normal cellular DNA (22) .
We have developed a method for cell type-and developmental stage-specific gene ablation by using transgenic BACs. We would like to propose that this method could be used in a variety of different settings to achieve developmentally restricted gene expression. BAC transgene complementation for programmed gene extinction has many of the same advantages as inducible gene targeting. Potential disadvantages of the BAC approach include: (i) loss of expression is not inducible; (ii) the requirement of a null mutant for complementation; (iii) the potential for variegated or abnormal BAC transgene expression if the BAC does not contain all of the necessary cis elements. Advantages of the method include rapid BAC modification by homologous recombination in Escherichia coli and homogenous gene extinction or activation in a cell type-specific fashion without exogenous agents for gene deletion. Ig␤ Expression Is Essential for Precursor B Cell Survival. When a lox-flanked Ig gene was deleted from mature B cells by inducible Cre expression the cells underwent programmed cell death and it was proposed that apoptosis is a physiologic response to disruption of the BCR (4). Ig deletion also resulted in loss of preB and immature B cells (4) . However, the possible role of BCR in preB and immature B cell survival could not be assessed because Ig deletion by Cre induction abrogated B cell development after the proB cell stage and no further preB or immature B cells could be produced (4) . Our method of BAC complementation allowed us to determine that preBCR and BCR expression was essential for preB and immature B cell survival, respectively, and that these B cell precursors fail to be maintained in the absence of Ig␤.
Our in vitro experiments suggested that B cell precursors that lose BCR expression die by apoptosis. The finding that transgenic bcl-2 expression rescued receptorless B cells from apoptosis in Ig␤tg-Ig␤ mice in which B cell development does not proceed beyond the proB cell stage (27) . PreBCR expression is therefore required to produce cells that can be maintained by constitutive bcl-2 expression.
How does the BCR produce a survival signal? Three mechanisms have been considered to explain how BCR expression might protect B cells from programmed cell death. First, receptor assembly on the cell surface might be sufficient to produce a constitutive survival signal (28) . Alternatively the tonic signal might be produced by low-affinity interaction between mIg and self-antigens (29) . A third possibility is that loss of BCR expression results in the up-regulation of Fas and in the downregulation of MHC class I molecules, and these receptorless B cells are therefore recognized and killed by cytotoxic T or NK cells (4) . Our experiments do not distinguish between receptor aggregation and receptor engagement by self-antigen as the mechanisms for producing the survival signal. However, we can rule out a requirement for NK or cytotoxic T cells in receptorless B cell deletion, because purified B cell precursors died upon receptor deletion in vitro and therefore this response is cell autonomous. Whereas BCR crosslinking by antigen in mature B cells leads to proliferative responses and clonal expansion, BCR triggering in immature B cells induces tolerance responses including receptor editing, anergy and deletion by apoptosis (reviewed in ref. 25) . It has been proposed that these distinct biological responses are caused by differences in the signaling cascades activated by the Ig␣ and Ig␤ components of the BCR at different stages in development (30) . Our results show that Ig␤ and BCR expression are essential for preB and immature B cell survival and therefore a BCR signal that maintains B cell survival is a universal B cell function common to all stages of B cell development.
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